Skip to content

Vor Biopharma

US · VOR #3175 by market cap Listed 2021
19.19 +0.67 +3.62%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 18.09 -2.32%
After-hours 19.20 +0.05%
Overnight 18.40 -0.65%
25.1013.0019.192026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on VOR?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +81.5% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 12.7% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall B+

The radar needs all six factors. Available grades are shown below.

Valuation B

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 0.1x Better than 100%
P/E vs own 5-yr range 95th pctl Better than 8%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Return on equity -94.5% Better than 6%
Return on invested capital -77.0% Better than 3%
Momentum B+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -17.9% Better than 34%
6-month return 33.9% Better than 91%
12-month return (ex latest month) 145.1% Better than 98%
Distance below 52-week high 26.2% Better than 48%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 18.2x Better than 98%
Debt to assets 0.6% Better than 95%
Interest coverage -16.8x Better than 10%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 107.4% Better than 85%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -1.18%
1M +0.84%
3M -16.80%
6M +23.41%
YTD +46.71%
1Y +179.74%
3Y -43.22%
5Y -92.93%

Key statistics

Price & volume

Prev close
18.52
Open
18.14
Day range
17.99 - 19.93
Avg price
19.29
Volume
1.56M
Turnover
30.00M
Amplitude
10.48%
52-week range
7.21 - 26.00

Valuation

P/E
-0.27
P/E (TTM)
0.06
P/B
-8.59
EPS
-70.50
Net profit
-4.33B
Net assets
-137.18M

Share structure

Market cap
1.18B
Float cap
829.58M
Shares out
61.43M
Float shares
43.23M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2021-02-05
52-week range 64% of range
7.21 26.00

26.2% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+732.74K net over the window

Short interest

Shares short
7.50M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Vor Biopharma (VOR)?

Vor Biopharma last traded at 19.19. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Vor Biopharma's market cap?

About 1.18B.

What is the P/E ratio of Vor Biopharma?

The trailing twelve-month P/E is 0.06. The Valuation tab shows it against the stock's own five-year range.

Does Vor Biopharma pay a dividend?

Vor Biopharma does not currently pay a regular dividend.

Is Vor Biopharma a buy according to analysts?

The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 39.80, which implies 107.4% upside from the current price. This is not investment advice.

What is Vor Biopharma's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Vor Biopharma a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Vor Biopharma discussion 0 comments

Add a comment